Ketamine should not be reclassified as a Class A drug, say experts | UK News
Experts who advise the government on drug-related issues in the UK have said that ketamine should not be…
Amore Ital Living aims to transform how Jamaicans heal | News
Amore Ital Living is not merely a wellness brand. It is the product of survival, love and a…
All You Need to Know About Milestone Pharmaceuticals (MIST) Rating Upgrade to Strong Buy
Milestone Pharmaceuticals (MIST) appears an attractive pick, as it has been recently upgraded to a Zacks Rank #1…
Health Ministry outlines safe use of weight loss medications
Muscat: The Ministry of Health has issued guidance on the safe and responsible use of weight loss medications,…
CMS selects next batch of 15 high-cost medicines for third negotiation cycle
The Centers for Medicare & Medicaid Services (CMS) has announced the next 15 high-cost medicines up for price…
ACMD announces decision on the classification of ketamine
The ACMD has advised the government ketamine should remain a class B controlled substance, but that police forces and health…
TMPC shuts Nana Boakye Herbal Centre, sanctions others
The Traditional Medicine Practice Council (TMPC) has closed down Nana Boakye Herbal Centre and sanctioned several other facilities…
Woman, 32, Credits GLP-1 with Helping Her Stop Eating Noodle Sandwiches and ‘a Block of Chocolate’ a Day
Lynsey Macfadyen / SWNS (2) Lynsey Macfadyen before and after weight lossNEED TO KNOW Lynsey Macfadyen had struggled…
I was hooked on melatonin — AGZ gummies helped me sleep soundly again
New York Post may receive revenue from affiliate and advertising partnerships for sharing this content and/or when you…
U.S. names HIV, arthritis drugs for next Medicare price talks
Eli Lilly’s office in San Diego, Nov. 21, 2025. Mike Blake | Reuters The U.S. government on Tuesday…
Towards a National Medicines Record: what it might mean for patient safety and pharmacy practice
Australia’s Minister for Health has announced a National Medicines Record. What is it, and what will it achieve?…
Industry spars over FDA plan to cut comparative efficacy studies for biosimilars
Industry spars over FDA plan to cut comparative efficacy studies for biosimilars | RAPSRegulatory NewsJoanne S. EglovitchBiologics License…